drugset / Trial / NCT06034886
Expanded Access Protocol of Troriluzole in Patients With Spinocerebellar Ataxia (SCA)
Summary
The purpose of this expanded access protocol is to provide access to the investigational drug troriluzole in patients with spinocerebellar ataxia (SCA).
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Troriluzole | Peptide | 140 mg | Oral |
| Subject | Troriluzole | Peptide | 200 mg | Oral |
| Subject | Troriluzole | Peptide | 280 mg | Oral |